Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

CD28 Signaling Controls Metabolic Fitness of Pathogenic T Cells in Medium and Large Vessel Vasculitis.

Zhang H, Watanabe R, Berry GJ, Nadler SG, Goronzy JJ, Weyand CM.

J Am Coll Cardiol. 2019 Apr 16;73(14):1811-1823. doi: 10.1016/j.jacc.2019.01.049.

PMID:
30975299
2.

Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.

Spergel SH, Mertzman ME, Kempson J, Guo J, Stachura S, Haque L, Lippy JS, Zhang RF, Galella M, Pitt S, Shen G, Fura A, Gillooly K, McIntyre KW, Tang V, Tokarski J, Sack JS, Khan J, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, Schieven GL, Wrobleski ST, Pitts WJ.

ACS Med Chem Lett. 2019 Feb 13;10(3):306-311. doi: 10.1021/acsmedchemlett.8b00508. eCollection 2019 Mar 14.

PMID:
30891131
3.

Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers.

Menard LC, Fischer P, Kakrecha B, Linsley PS, Wambre E, Liu MC, Rust BJ, Lee D, Penhallow B, Manjarrez Orduno N, Nadler SG.

Front Immunol. 2018 Nov 26;9:2728. doi: 10.3389/fimmu.2018.02728. eCollection 2018.

4.

Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.

Manjarrez-Orduño N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C, Cunningham M, Greenawalt D, Patel V, Yang M, Golhar R, Carman JA, Lezhnin S, Dai H, Kayne PS, Suchard SJ, Bernstein SH, Nadler SG.

Front Immunol. 2018 Aug 3;9:1613. doi: 10.3389/fimmu.2018.01613. eCollection 2018.

5.

Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.

Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG.

Arthritis Rheumatol. 2018 Aug;70(8):1331-1342. doi: 10.1002/art.40476. Epub 2018 Jul 12.

6.

A patient's perspective of chronic pain.

Nadler SG.

Pain Manag. 2017 Jul;7(4):239-242. doi: 10.2217/pmt-2016-0061. Epub 2017 Jul 12.

PMID:
28699410
7.

Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.

Hynes J Jr, Wu H, Kempson J, Duan JJ, Lu Z, Jiang B, Stachura S, Tokarski JS, Sack JS, Khan JA, Lippy JS, Zhang RF, Pitt S, Shen G, Gillooly K, McIntyre K, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, Fura A, Schieven GL, Pitts WJ, Wrobleski ST.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3101-3106. doi: 10.1016/j.bmcl.2017.05.043. Epub 2017 May 15.

PMID:
28539220
8.

B cells from African American lupus patients exhibit an activated phenotype.

Menard LC, Habte S, Gonsiorek W, Lee D, Banas D, Holloway DA, Manjarrez-Orduno N, Cunningham M, Stetsko D, Casano F, Kansal S, Davis PM, Carman J, Zhang CK, Abidi F, Furie R, Nadler SG, Suchard SJ.

JCI Insight. 2016 Jun 16;1(9):e87310. doi: 10.1172/jci.insight.87310.

9.

Functional Antagonism of Human CD40 Achieved by Targeting a Unique Species-Specific Epitope.

Yamniuk AP, Suri A, Krystek SR, Tamura J, Ramamurthy V, Kuhn R, Carroll K, Fleener C, Ryseck R, Cheng L, An Y, Drew P, Grant S, Suchard SJ, Nadler SG, Bryson JW, Sheriff S.

J Mol Biol. 2016 Jul 17;428(14):2860-79. doi: 10.1016/j.jmb.2016.05.014. Epub 2016 May 21.

10.

Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Krishna M, Nadler SG.

Front Immunol. 2016 Feb 2;7:21. doi: 10.3389/fimmu.2016.00021. eCollection 2016. Review.

11.

Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells.

Patakas A, Ji RR, Weir W, Connolly SE, Benson RA, Nadler SG, Brewer JM, McInnes IB, Garside P.

Arthritis Rheumatol. 2016 Mar;68(3):627-38. doi: 10.1002/art.39470.

12.

Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699.

Yang Z, Wang H, Salcedo TW, Suchard SJ, Xie JH, Schneeweis LA, Fleener CA, Calore JD, Shi R, Zhang SX, Rodrigues AD, Car BD, Marathe PH, Nadler SG.

J Pharmacol Exp Ther. 2015 Dec;355(3):506-15. doi: 10.1124/jpet.115.227249. Epub 2015 Oct 6.

PMID:
26442523
13.

Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression.

Liu D, Suchard SJ, Nadler SG, Ford ML.

PLoS One. 2015 Jun 22;10(6):e0130490. doi: 10.1371/journal.pone.0130490. eCollection 2015.

14.

Improving the pharmacokinetic and CYP inhibition profiles of azaxanthene-based glucocorticoid receptor modulators-identification of (S)-5-(2-(9-fluoro-2-(4-(2-hydroxypropan-2-yl)phenyl)-5H-chromeno[2,3-b]pyridin-5-yl)-2-methylpropanamido)-N-(tetrahydro-2H-pyran-4-yl)-1,3,4-thiadiazole-2-carboxamide (BMS-341).

Yang MG, Dhar TG, Xiao Z, Xiao HY, Duan JJ, Jiang B, Galella MA, Cunningham M, Wang J, Habte S, Shuster D, McIntyre KW, Carman J, Holloway DA, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS.

J Med Chem. 2015 May 28;58(10):4278-90. doi: 10.1021/acs.jmedchem.5b00257. Epub 2015 May 7.

PMID:
25905990
15.

Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis.

Tanaka H, Yang GX, Tomiyama T, Tsuneyama K, Zhang W, Leung PS, Coppel RL, Joh T, Nadler SG, Ansari AA, Bowlus C, Gershwin ME.

Clin Exp Immunol. 2015 Jun;180(3):371-82. doi: 10.1111/cei.12581.

16.

Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.

Duan JJ, Lu Z, Jiang B, Yang BV, Doweyko LM, Nirschl DS, Haque LE, Lin S, Brown G, Hynes J Jr, Tokarski JS, Sack JS, Khan J, Lippy JS, Zhang RF, Pitt S, Shen G, Pitts WJ, Carter PH, Barrish JC, Nadler SG, Salter-Cid LM, McKinnon M, Fura A, Schieven GL, Wrobleski ST.

Bioorg Med Chem Lett. 2014 Dec 15;24(24):5721-5726. doi: 10.1016/j.bmcl.2014.10.061. Epub 2014 Oct 24.

PMID:
25453808
17.

Discovery of acylurea isosteres of 2-acylaminothiadiazole in the azaxanthene series of glucocorticoid receptor agonists.

Gong H, Yang M, Xiao Z, Doweyko AM, Cunningham M, Wang J, Habte S, Holloway D, Burke C, Shuster D, Gao L, Carman J, Somerville JE, Nadler SG, Salter-Cid L, Barrish JC, Weinstein DS.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3268-73. doi: 10.1016/j.bmcl.2014.06.010. Epub 2014 Jun 13.

PMID:
24980053
18.

2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses.

Liu D, Krummey SM, Badell IR, Wagener M, Schneeweis LA, Stetsko DK, Suchard SJ, Nadler SG, Ford ML.

J Exp Med. 2014 Feb 10;211(2):297-311. doi: 10.1084/jem.20130902. Epub 2014 Feb 3.

19.

A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety.

Suchard SJ, Davis PM, Kansal S, Stetsko DK, Brosius R, Tamura J, Schneeweis L, Bryson J, Salcedo T, Wang H, Yang Z, Fleener CA, Ignatovich O, Plummer C, Grant S, Nadler SG.

J Immunol. 2013 Nov 1;191(9):4599-610. doi: 10.4049/jimmunol.1300470. Epub 2013 Sep 30.

20.

Heterocyclic glucocorticoid receptor modulators with a 2,2-dimethyl-3-phenyl-N-(thiazol or thiadiazol-2-yl)propanamide core.

Xiao HY, Wu DR, Sheppeck JE 2nd, Habte SF, Cunningham MD, Somerville JE, Barrish JC, Nadler SG, Dhar TG.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5571-4. doi: 10.1016/j.bmcl.2013.08.049. Epub 2013 Aug 16.

PMID:
24011644
21.

An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig.

Pinelli DF, Wagener ME, Liu D, Yamniuk A, Tamura J, Grant S, Larsen CP, Suri A, Nadler SG, Ford ML.

Am J Transplant. 2013 Nov;13(11):3021-30. doi: 10.1111/ajt.12417. Epub 2013 Sep 5.

22.

Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.

Sheppeck JE 2nd, Gilmore JL, Xiao HY, Dhar TG, Nirschl D, Doweyko AM, Sack JS, Corbett MJ, Malley MF, Gougoutas JZ, Mckay L, Cunningham MD, Habte SF, Dodd JH, Nadler SG, Somerville JE, Barrish JC.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5442-7. doi: 10.1016/j.bmcl.2013.06.089. Epub 2013 Jul 9.

PMID:
23953070
23.

Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.

Gilmore JL, Sheppeck JE 2nd, Wang J, Dhar TG, Cavallaro C, Doweyko AM, Mckay L, Cunningham MD, Habte SF, Nadler SG, Dodd JH, Somerville JE, Barrish JC.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5448-51. doi: 10.1016/j.bmcl.2013.06.085. Epub 2013 Jul 4.

PMID:
23916594
24.

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis.

Cutolo M, Nadler SG.

Autoimmun Rev. 2013 May;12(7):758-67. doi: 10.1016/j.autrev.2013.01.001. Epub 2013 Jan 20. Review.

PMID:
23340277
25.

Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791826).

Weinstein DS, Gong H, Doweyko AM, Cunningham M, Habte S, Wang JH, Holloway DA, Burke C, Gao L, Guarino V, Carman J, Somerville JE, Shuster D, Salter-Cid L, Dodd JH, Nadler SG, Barrish JC.

J Med Chem. 2011 Oct 27;54(20):7318-33. doi: 10.1021/jm200879j. Epub 2011 Oct 3.

PMID:
21899328
26.

Transcriptional profiling of liver and effect of glucocorticoids in a rat adjuvant-induced arthritis model.

Song YL, Foster WR, Shuster DJ, Nadler SG, Salter-Cid L, Sasseville VG.

Vet Pathol. 2011 Jul;48(4):885-95. doi: 10.1177/0300985810390018. Epub 2010 Dec 13.

PMID:
21149847
27.

Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists.

Yang BV, Weinstein DS, Doweyko LM, Gong H, Vaccaro W, Huynh T, Xiao HY, Doweyko AM, McKay L, Holloway DA, Somerville JE, Habte S, Cunningham M, McMahon M, Townsend R, Shuster D, Dodd JH, Nadler SG, Barrish JC.

J Med Chem. 2010 Dec 9;53(23):8241-51. doi: 10.1021/jm100957a. Epub 2010 Nov 12.

PMID:
21073190
28.

Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells.

Platt AM, Gibson VB, Patakas A, Benson RA, Nadler SG, Brewer JM, McInnes IB, Garside P.

J Immunol. 2010 Aug 1;185(3):1558-67. doi: 10.4049/jimmunol.1001311. Epub 2010 Jul 2.

29.

Targeting lymphocyte co-stimulation: from bench to bedside.

Felix NJ, Suri A, Salter-Cid L, Nadler SG, Gujrathi S, Corbo M, Aranda R.

Autoimmunity. 2010 Nov;43(7):514-25. doi: 10.3109/08916931003674741. Review.

PMID:
20429850
30.

Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.

Xiao HY, Wu DR, Malley MF, Gougoutas JZ, Habte SF, Cunningham MD, Somerville JE, Dodd JH, Barrish JC, Nadler SG, Dhar TG.

J Med Chem. 2010 Feb 11;53(3):1270-80. doi: 10.1021/jm901551w.

PMID:
20047280
31.

Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus.

Teijaro JR, Njau MN, Verhoeven D, Chandran S, Nadler SG, Hasday J, Farber DL.

J Immunol. 2009 Jun 1;182(11):6834-43. doi: 10.4049/jimmunol.0803860.

32.

The clinical utility of inhibiting CD28-mediated costimulation.

Linsley PS, Nadler SG.

Immunol Rev. 2009 May;229(1):307-21. doi: 10.1111/j.1600-065X.2009.00780.x. Review.

PMID:
19426230
33.

Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.

Hoff H, Knieke K, Cabail Z, Hirseland H, Vratsanos G, Burmester GR, Jorch G, Nadler SG, Bröker B, Hebel K, Brunner-Weinzierl MC.

J Immunol. 2009 May 1;182(9):5342-51. doi: 10.4049/jimmunol.0801624.

34.

Discovery of novel dihydro-9,10-ethano-anthracene carboxamides as glucocorticoid receptor modulators.

Yang BV, Vaccaro W, Doweyko AM, Doweyko LM, Huynh T, Tortolani D, Nadler SG, McKay L, Somerville J, Holloway DA, Habte S, Weinstein DS, Barrish JC.

Bioorg Med Chem Lett. 2009 Apr 15;19(8):2139-43. doi: 10.1016/j.bmcl.2009.03.006. Epub 2009 Mar 9.

PMID:
19321341
35.

Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.

Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):1935-8. doi: 10.1016/j.bmcl.2009.02.060. Epub 2009 Feb 21.

PMID:
19272774
36.

Abatacept does not induce direct gene expression changes in antigen-presenting cells.

Carman JA, Davis PM, Yang WP, Zhu J, Chang H, He A, Truong A, Suchard SJ, Nadler SG.

J Clin Immunol. 2009 Jul;29(4):479-89. doi: 10.1007/s10875-009-9282-z. Epub 2009 Mar 4.

PMID:
19259798
37.

CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis.

Tang AL, Teijaro JR, Njau MN, Chandran SS, Azimzadeh A, Nadler SG, Rothstein DM, Farber DL.

J Immunol. 2008 Aug 1;181(3):1806-13.

38.

Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction.

Davis PM, Nadler SG, Stetsko DK, Suchard SJ.

Clin Immunol. 2008 Jan;126(1):38-47. Epub 2007 Oct 22.

PMID:
17945538
39.

Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ.

J Rheumatol. 2007 Nov;34(11):2204-10. Epub 2007 Sep 1.

PMID:
17787038
40.

Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice.

Bigbee CL, Gonchoroff DG, Vratsanos G, Nadler SG, Haggerty HG, Flynn JL.

Arthritis Rheum. 2007 Aug;56(8):2557-65.

41.

Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway.

Ndejembi MP, Teijaro JR, Patke DS, Bingaman AW, Chandok MR, Azimzadeh A, Nadler SG, Farber DL.

J Immunol. 2006 Dec 1;177(11):7698-706.

42.

Direct association of tristetraprolin with the nucleoporin CAN/Nup214.

Carman JA, Nadler SG.

Biochem Biophys Res Commun. 2004 Mar 5;315(2):445-9.

PMID:
14766228
43.

Phosphodiesterase 7A-deficient mice have functional T cells.

Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Watson AJ.

J Immunol. 2003 Dec 15;171(12):6414-20.

44.

An intracellular targeted NLS peptide inhibitor of karyopherin alpha:NF-kappa B interactions.

Cunningham MD, Cleaveland J, Nadler SG.

Biochem Biophys Res Commun. 2003 Jan 10;300(2):403-7.

PMID:
12504098
45.
46.

Role of NF-kappaB in endotoxemia-induced alterations of lung neutrophil apoptosis.

Kupfner JG, Arcaroli JJ, Yum HK, Nadler SG, Yang KY, Abraham E.

J Immunol. 2001 Dec 15;167(12):7044-51.

47.

Nuclear localization of the tyrosine kinase Itk and interaction of its SH3 domain with karyopherin alpha (Rch1alpha).

Perez-Villar JJ, O'Day K, Hewgill DH, Nadler SG, Kanner SB.

Int Immunol. 2001 Oct;13(10):1265-74.

PMID:
11581171
48.
49.

A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease.

Fujihara SM, Cleaveland JS, Grosmaire LS, Berry KK, Kennedy KA, Blake JJ, Loy J, Rankin BM, Ledbetter JA, Nadler SG.

J Immunol. 2000 Jul 15;165(2):1004-12.

50.

Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex.

Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H, Pushkarsky T, Nadler SG, Bukrinsky M.

J Mol Biol. 2000 Jun 2;299(2):359-68.

PMID:
10860744

Supplemental Content

Loading ...
Support Center